- You can view the full Amgen Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The drugs industry closed the day up 0.7%. K-V Pharmaceutical Company ( KV.A), Cyclacel Pharmaceuticals Inc ( CYCC), K-V Pharmaceutical Company ( KV.B), and Uluru Inc ( ULU) were all winners today within the drugs industry with Amgen Inc ( AMGN) being today's featured drugs winner. Amgen Inc rose 34 cents (0.6%) to $56.98 on light volume. Throughout the day, 4.7 million shares of Amgen Inc exchanged hands as compared to its average daily volume of seven million shares. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen Inc has a market cap of $52.8 billion and is part of the health care sector. The company has a P/E ratio of 11.9, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 3.2% year to date as of the close of trading on Wednesday. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
